Compare VTRS & HST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTRS | HST |
|---|---|---|
| Founded | 1961 | 1927 |
| Country | United States | United States |
| Employees | 30000 | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.7B | 15.3B |
| IPO Year | 2019 | 1998 |
| Metric | VTRS | HST |
|---|---|---|
| Price | $16.43 | $23.38 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 14 |
| Target Price | $13.50 | ★ $20.75 |
| AVG Volume (30 Days) | ★ 8.8M | 8.2M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | 3.21% | ★ 4.51% |
| EPS Growth | N/A | ★ 11.11 |
| EPS | 0.15 | ★ 0.72 |
| Revenue | ★ $14,299,900,000.00 | $5,387,000,000.00 |
| Revenue This Year | $4.41 | $0.10 |
| Revenue Next Year | $1.96 | $1.09 |
| P/E Ratio | $117.67 | ★ $34.90 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.25 | $15.18 |
| 52 Week High | $18.07 | $25.71 |
| Indicator | VTRS | HST |
|---|---|---|
| Relative Strength Index (RSI) | 66.57 | 40.61 |
| Support Level | $15.82 | $22.64 |
| Resistance Level | N/A | $25.56 |
| Average True Range (ATR) | 0.44 | 0.58 |
| MACD | 0.02 | -0.06 |
| Stochastic Oscillator | 88.38 | 8.40 |
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
Host Hotels & Resorts owns 78 predominantly urban and resort upper-upscale and luxury hotel properties representing over 42,000 rooms, mainly in the United States. Host sold off the company's interests in a joint venture owning a portfolio of hotels throughout Europe and also sold other joint ventures that owned properties in Asia and the United States. The majority of Host's portfolio operates under the Marriott and Starwood brands.